| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695366 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
David E. Cohn, Michael W. Sill, Joan L. Walker, David O'Malley, Christa I. Nagel, Teresa L. Rutledge, William Bradley, Debra L. Richardson, Katherine M. Moxley, Carol Aghajanian,